NCT04768972Phase 3Active not recruiting

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

Study sponsor: Ionis Pharmaceuticals, Inc. · IONS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-17Actual
Enrollment · participants89Actual
Source updated2026-07-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jun 2026. After: 17 Jun 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview